Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803584 | 1.00 | ADRB2 (0.71) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1180240 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1796166 | 0.98 | ADRB2 (0.69) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Acetic Acid SCHEMBL1801841 | 0.93 | ADRB2 (0.67) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Acetic Acid SCHEMBL1803737 | 0.93 | ADRB2 (0.67) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL14291930 | 0.88 | ADRB2 (0.75) | ADRB2ADRB1DRD3 | |
| SCHEMBL13754327 | 0.84 | ADRB2 (0.66) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL13711689 | 0.84 | ADRB2 (0.54) | ADRB2ADRB1DRD3 | |
| SCHEMBL14027825 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1DRD3 | |
| SCHEMBL14382684 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074816-B | Heterocyclic derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-107108562-B | With β2ReceptorsNitrogen-containing heterocyclic ring derivative with agonistic and M receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-107074816-A | A kind of Hete rocyclic derivatives and preparation method thereof and in purposes pharmaceutically | 四川海思科制药有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002261-A1 | Process | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2012156693-A1 | PROCESS | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| EP-1937656-A4 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS BETA 2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2010-05-05 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1957471-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS 2 ADRENOCEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1937656-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS BETA 2 ADRENOCEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008023157-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007027134-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | ADRB2 1366/4885ADRB1 970/4885DRD3 598/4885 |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885DRD3 576/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | ADRB2 218/4885ADRB1 199/4885DRD3 2985/4885 |
| US-20160002261-A1 | Process | CYP1A2, CYP11B2, CYP2F1 | ADRB2 1674/4885ADRB1 2749/4885DRD3 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.